16
Participants
Start Date
October 3, 2018
Primary Completion Date
February 14, 2019
Study Completion Date
March 14, 2019
Aflibercept (EYLEA, BAY86-5321)
2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
Topical IOP-lowering drugs
A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
University of Fukui Hospital, Yoshida
Tsukazaki Hospital, Himeji
Kanazawa University Hospital, Kanazawa
St. Marianna University School of Medicine Hospital, Kawasaki
Osaka University Hospital, Suita
Takatsuki Red Cross Hospital, Takatsuki
Shimane University Hospital, Izumo
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Bayer
INDUSTRY